A Cancer Therapy Results Of 50 Cases Pdf

[Lilliana Adames]

Fordecades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. These continue to be critical mainstays of treatment, but new categories of treatment have recently helped transform the treatment picture for people with cancer.

But another form of immunotherapy, called CAR T-cell therapy, has also generated substantial excitement among researchers and oncologists. Although CAR T-cell therapies are not as widely used as immune checkpoint inhibitors, they have shown the same ability to eradicate very advanced leukemias and lymphomas and to keep the cancer at bay for many years.

Since 2017, six CAR T-cell therapies have been approved by the Food and Drug Administration (FDA). All are approved for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

Despite the excitement around these therapies, they lead to long-term survival in fewer than half of the patients treated. They have also come under criticism for their cost, which, in the case of the most recently approved CAR T-cell therapy, is more than $450,000.

Nevertheless, after years of painstaking research, CAR T-cell therapies have entered the mainstream of cancer treatment, said Steven Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI's Center for Cancer Research (CCR), an immunotherapy and CAR T-cell therapy pioneer.

CAR T cells are the equivalent of "giving patients a living drug," explained Renier J. Brentjens, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center in New York, another early leader in the CAR T-cell field.

Currently available CAR T-cell therapies are customized for each individual patient. They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells.

These receptors are "synthetic molecules, they don't exist naturally," explained Carl June, M.D., of the University of Pennsylvania Abramson Cancer Center, another leader in the cellular therapy field.

More than 80% of children diagnosed with ALL that arises in B cells, the predominant type of pediatric ALL, will be cured by intensive chemotherapy. But effective treatments have been limited for patients whose cancers return, or relapse, after chemotherapy or a stem-cell transplant.

An NCI-led research team, for example, recently reported on long-term follow-up from children with relapsed ALL who had been treated with CAR T cells as part of a clinical trial. More than half the children went on to receive a potentially curative stem-cell transplant, they found, and approximately 60% of those children were still alive 5 years later without their cancer coming back or the children experiencing any disease-related problems.

The progress made with CAR T-cell therapy in children with ALL "has been fantastic," said Terry Fry, M.D., who has led several clinical trials of CAR-T cell therapies at NCI and, more recently, at Children's Hospital Colorado. As CAR T-cell therapy has become more widely available, Dr. Fry said, it has rapidly become the standard of care for children with relapsed ALL.

Like all cancer treatments, CAR T-cell therapies can cause severe side effects, including a mass die-off of antibody-producing B cells and infections. One of the most frequent and serious side effects is cytokine release syndrome (CRS).

As part of their immune-related duties, T cells release cytokines, chemical messengers that help stimulate and direct the immune response. In the case of CRS, the infused T cells flood the bloodstream with cytokines, causing serious side effects, including dangerously high fevers and precipitous drops in blood pressure. In some cases, severe CRS can be fatal.

In many patients, both children and adults, mild forms of CRS can be managed with standard supportive therapies, including steroids. And as researchers have gained more experience with CAR T-cell therapy, they've discovered ways to better manage the more serious cases of CRS.

A big part of that management is the drug tocilizumab (Actemra). This drug, initially used to treat inflammatory conditions like juvenile arthritis, blocks the activity of IL-6, a cytokine that is often secreted in large amounts by T cells and macrophages.

Other treatments for ICANS are being investigated. Smaller studies, for example, have found that anakinra (Kineret), which is used to treat rheumatoid arthritis, may help prevent severe ICANS in patients treated with CAR T-cell therapies.

Research on CAR T cells is continuing at a swift pace, including hundreds of ongoing clinical trials. Part of this expansion is a product of researchers having identified additional antigens on tumor cells that might be good targets for CAR T cells.

Although CD19 and BCMA are the only antigens for which there are FDA-approved CAR T-cell therapies, CAR T-cell therapies have been developed that target other antigens commonly found in blood cancers, including therapies that target multiple antigens at one time.

Another obstacle with solid tumors is their surrounding environment. Physical barriers, for example, can prevent the infused CAR T cells from reaching tumor cells. Other components of the microenvironment, such as immune-suppressing molecules produced by tumor cells or other immune cells, can cause CAR T cells to malfunction, leaving them unable to carry out their cell-killing duties.

For the GD2 CAR T-cell trial, how it was initially envisioned and how it has been carried out are quite different, Dr. Mackall explained at the 2021 annual meeting of the Society for Immunotherapy of Cancer.

Initially, patients were going to be treated only with an initial intravenous infusion of CAR T cells. But results from animal model studies of a similar CAR T-cell therapy led the researchers to alter the trial: patients who respond to the initial intravenous infusion were given additional smaller doses infused directly into the brain.

All of the FDA-approved CAR T-cell therapies rely on a disarmed virus to deliver the genetic material into T cells to produce the CAR. But for the off-the-shelf CAR T cells now being tested in small clinical trials, gene-editing technologies like TALON and CRISPR are being used to induce the donated T cells to produce CARs.

Other off-the-shelf CARs also use a different type of immune cell, called natural killer (NK) cells. Much of this research is still in its early days, but some CAR NK cell therapies are already being tested in small clinical trials.

And not only is the source of T cells and the type of immune cell being reconsidered, but so is where the therapies are actually made. Several research groups, for instance, are using nanotechnology and mRNA-based approaches that allow CAR T cells to be created inside the body.

Recently, in two large clinical trials, CAR T-cell therapy proved to be more effective than the standard treatment for patients with non-Hodgkin lymphoma whose cancer returned after their initial, or first-line, chemotherapy.

CAR T cells have garnered the lion's share of attention when it comes to cellular therapies. But other types of cellular therapies have also shown promise in small clinical trials, including in patients with solid tumors.

The other type of cellular therapy involves engineering patients' T cells to express a specific T-cell receptor (TCR). Unlike CARs, which use portions of synthetic antibodies that can recognize specific antigens only on the surface of cells, TCRs use naturally occurring receptors that can also recognize antigens that are inside tumor cells.

Gerson described his approach in the book A Cancer Therapy: Results of 50 Cases (1958). The National Cancer Institute evaluated Gerson's claims and concluded that his data showed no benefit from his treatment.[4] The therapy is both ineffective and dangerous.[3][5][6] Serious illness and deaths have resulted from Gerson therapy.[3][7]

Gerson was born to a Jewish family in Wongrowitz, German Empire (Wągrowiec, now in Poland), on October 18, 1881. In 1909, he graduated from the Albert Ludwig University of Freiburg. He began practicing medicine at age 28 in Breslau (Wrocław, now in Poland), later specializing in internal medicine and nerve diseases in Bielefeld.[8] By 1927, he was specializing in the treatment of tuberculosis, developing the Gerson-Sauerbruch-Hermannsdorfer diet, claiming it was a major advance in the treatment of tuberculosis.[8] Initially, he used his therapy as a supposed treatment for migraine headaches and tuberculosis. In 1928, he began to use it as a claimed treatment for cancer.[9] When the Nazis came to power in 1933 Gerson left Germany, emigrating to Vienna, where he worked in the West End Sanatorium. Gerson spent two years in Vienna, before moving to France in 1935, associating with a clinic near Paris before moving to London in 1936. Shortly thereafter, he moved to the United States, settling in New York City.[8]

Gerson emigrated to the United States in 1936, passed his medical board examination, and became a U.S. citizen in 1942.[8] In the U.S., Gerson applied his dietary therapy to several cancer patients, claiming good results, but other workers found his methodology and claims unconvincing. Proponents of Gerson therapy believe a conspiracy headed by the medical establishment prevented Gerson from publishing proof that his therapy worked.[10] In 1958, Gerson published a book in which he claimed to have cured 50 terminal cancer patients: A Cancer Therapy: Results of 50 Cases. In 1953, Gerson's malpractice insurance was discontinued and, in 1958, his medical license in New York was suspended for two years.[8][11]

Gerson therapy is based on the belief that cancer is the result of a deteriorating metabolism from an impaired liver function.[3] Gerson therapy aims to restore the body to health by repairing the liver and return metabolism to its normal state.[4] The therapy promotes the idea that cancer is caused by alteration of cell metabolism by processed food and toxic environmental substances which alter its sodium and potassium content.[14] It also emphasizes limiting sodium and increasing potassium intake to detoxify the liver. Coffee enemas are said to cause excretion of toxic breakdown products by the liver and through the colon wall. None of these ideas are supported by scientific research.[14] Gerson commented that his therapy aimed to create a "near normal condition of the oxidizing system in the body, to which malignant cells with the fermentation system cannot adapt".[3]

3a8082e126